Clik here to view.
Gearing up: HBA Leadership Conference
Two thousand and eight seems to be a year of unprecedented female leadership. Forget for a second (if you can) the run-off for the Presidential election. If you just consider healthcare, the ladies are...
View ArticleTakeda Changes Dexlansoprazole Brand Name From Kapidex to Dexilant
Takeda’s US subsidiary launched its proton pump inhibitor dexlansoprazole last February under the name Kapidex. No one thought they’d have to find a new name a year later. But shortly after the launch,...
View ArticleAvandia Trial in Trouble
GSK’s Avandia just won’t stay out of the news. Now comes a report from The Wall Street Journal that the FDA is considering dealing the beleaguered diabetes drug another blow by stopping one of its...
View ArticleClik here to view.
Takeda Launches New Plan, Cuts US Jobs
Image via Wikipedia The Japanese are taking a play from the US pharmaceutical industry’s rulebook and restructuring itself under the auspices of a fun catch phrase: “Transformation for a New Takeda.”...
View ArticleNew York Pharma Forum: Together We Stand
Participants in the 23rd Annual NYPF General Assembly last Friday outlined the many challenges facing industry, and the importance of collaboration as a way to move forward. It’s no secret that the...
View ArticleFrontrunners in Innovation: New Drug Approvals 2013
Frontrunners in Innovation: New Drug Approvals 2013 Trying to nail down the actual number of new drugs approvals in 2013 is like trying to swat a fly—it can be highly illusive. Safe to say, however,...
View ArticleClik here to view.
From Cyprus to Cambridge: The Rise of Anna Protopapas, Millennium Takeda's...
Takeda’s Oncology Taskmaster Millennium Takeda’s new president, Anna Protopapas, explains to Pharm exec’s William Looney the life choices that brought her from Cyprus to Cambridge—and a lead position...
View ArticleTakeda's New Vaccines Division Charts Course to Global Growth
Today’s vaccines business represents an almost perfect world for big Pharma. There is a vast landscape of unmet medical need; lots of new science; longer product life cycles, with low exposure to...
View Article
